Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Archives of Oto-Rhino-Laryngology

05.04.2024 | Otology

Natural history of hearing and tumor growth in vestibular schwannoma in neurofibromatosis type 2-related schwannomatosis

verfasst von: Takeshi Wakabayashi, Ryota Tamura, Kosuke Karatsu, Makoto Hosoya, Takanori Nishiyama, Yasuhiro Inoue, Kaoru Ogawa, Jin Kanzaki, Masahiro Toda, Hiroyuki Ozawa, Naoki Oishi

Erschienen in: European Archives of Oto-Rhino-Laryngology

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To determine the natural history of hearing loss and tumor volume in patients with untreated neurofibromatosis type 2 (NF2)-related schwannomatosis. Moreover, we statistically examined the factors affecting hearing prognosis.

Methods

This retrospective cohort study was conducted on 37 ears of 24 patients with NF2-related vestibular schwannomatosis followed up without treatment for more than 1 year. We obtained detailed chronological changes in the PTA and tumor volume in each case over time, and the rate of change per year was obtained. Multivariate analysis was also conducted to investigate factors associated with changes in hearing.

Results

The average follow-up period was approximately 9 years, and hearing deteriorated at an average rate of approximately 4 dB/year. The rate of maintaining effective hearing decreased from 30 ears (81%) at the first visit to 19 ears (51%) at the final follow-up. The average rate of change in tumor growth for volume was approximately 686.0 mm3/year. This study revealed that most patients with NF2 experienced deterioration in hearing acuity and tumor growth during the natural course. A correlation was observed between an increase in tumor volume and hearing loss (r = 0.686; p < 0.001).

Conclusions

Although the hearing preservation rate in NF2 cases is poor with the current treatment methods, many cases exist in which hearing acuity deteriorates, even during the natural course. Patients with an increased tumor volume during the follow-up period were more likely to experience hearing deterioration.
Trial registration number 20140242 (date of registration: 27 October 2014).
Literatur
1.
Seizinger BR, Martuza RL, Gusella JF (1986) Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 322:644–647PubMedCrossRef
2.
Plotkin SR, Messiaen L, Legius E et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24:1967–1977PubMedCrossRef
3.
Forde C, King AT, Rutherford SA et al (2021) Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 23:1113–1124PubMedCrossRef
4.
Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93–97PubMedCrossRef
5.
Evans DG, Howard E, Giblin C et al (2010) Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 152A:327–332PubMedCrossRef
6.
Antinheimo J, Sankila R, Carpén O, Pukkala E, Sainio M, Jääskeläinen J (2000) Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 54:71–76PubMedCrossRef
7.
Evans DG, Bowers NL, Tobi S et al (2018) Schwannomatosis: a genetic and epidemiological study. J Neurol Neurosurg Psychiatry 89:1215–1219PubMedCrossRef
8.
Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N (1994) Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:450–461PubMedCrossRef
9.
10.
Otsuka G, Saito K, Nagatani T, Yoshida J (2003) Age at symptom onset and long-term survival in patients with neurofibromatosis type 2. J Neurosurg 99:480–483PubMedCrossRef
11.
Saito K (2004) Treatment of acoustic schwannomas associated with neurofibromatosis type 2. Jpn J Neurosurg 13:427–432CrossRef
12.
Samii M, Gerganov V, Samii A (2008) Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results. Prog Neurol Surg 21:169–175PubMedCrossRef
13.
Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM (2021) New developments in neurofibromatosis type 2 and vestibular schwannoma. Neurooncol Adv. 3:vdaa153PubMed
14.
Plotkin SR, Merker VL, Halpin C et al (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 336:1046–1052CrossRef
15.
Mautner VF, Nguyen R, Kutta H et al (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 121:14–18CrossRef
16.
Morris KA, Golding JF, Axon PR et al (2016) Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 3:281–89PubMedPubMedCentral
17.
Tamura R, Fujioka M, Morimoto Y et al (2019) A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2. Nat Commun 10:5758PubMedPubMedCentralCrossRef
18.
Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma) (1995) American academy of otolaryngology-head and neck surgery foundation, INC. Otolaryngol Head Neck Surg. 113:179–80
19.
Koos WT, Day JD, Matula C et al (1998) Neurotopographic considerations in the microsurgical treatment of small acoustic neurinomas. J Neurosurg 88:506–512PubMedCrossRef
20.
21.
Kontorinis G, Nichani J, Freeman SR et al (2015) Progress of hearing loss in neurofibromatosis type 2: implications for future management. Eur Arch Otorhinolaryngol 272:3143–3150PubMedCrossRef
22.
Stangerup SE, Caye-Thomasen P (2012) Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin North Am 45:257–268PubMedCrossRef
23.
24.
Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W 3rd, Plotkin SR (2016) Health-related quality of life of individuals with neurofibromatosis type 2: results from the NF2 natural history study. Otol Neurotol 37:574–579PubMedCrossRef
25.
Iwatate K, Yokoo K, Iwatate E et al (2017) Population characteristics and progressive disability in neurofibromatosis type 2. World Neurosurg 106:653–660PubMedCrossRef
26.
deTorres AT, Brewer CC, Zalewski CK et al (2018) Audiologic natural history of small volume cochleovestibular schwannomas in neurofibromatosis type 2. Otol Neurotol 39:357–364PubMedPubMedCentralCrossRef
27.
Fisher LM, Doherty JK, Lev MH, Slattery WH (2009) Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2. Otol Neurotol 30:835–841PubMedCrossRef
28.
Roosli C, Linthicum FH, Cureoglu S, Merchant SN (2012) Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity. Otol Neurotol 33:473–480PubMedPubMedCentralCrossRef
29.
Graamans K, Van Dilk JE, Janssen LW (2003) Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta Otolaryngol 123:51–54PubMedCrossRef
30.
Peyre M, Goutagny S, Bah A et al (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913PubMedCrossRef
31.
Yamazaki M, Naganawa S, Kawai H, Nihashi T, Fukatsu H, Nakashima T (2009) Increased signal intensity of the cochlea on pre- and post-contrast enhanced 3D-FLAIR in patients with vestibular schwannoma. Neuroradiology 51:855–863PubMedCrossRef
32.
Peyre M, Bernardeschi D, Sterkers O, Kalamarides M (2018) Natural history of vestibular schwannomas and hearing loss in NF2 patients. Neurochirurgie 64:342–347PubMedCrossRef
33.
Dilwali S, Landegger LD, Soares VY, Deschler DG, Stankovic KM (2015) Secreted factors from human vestibular schwannomas can cause cochlear damage. Sci Rep 5:18599PubMedPubMedCentralCrossRef
34.
Baser ME, Makariou EV, Parry DM (2002) Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 96:217–222PubMedCrossRef
35.
Baser ME, Mautner VF, Parry DM, Evan DG (2005) Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet 42:903–906PubMedPubMedCentralCrossRef
36.
Mautner VF, Baser ME, Thakkar SD, Feigen UM, Friedman JM, Kluwe L (2002) Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 96:223–228PubMedCrossRef
37.
Ito E, Saito K, Yatsuya H, Nagatani T, Otsuka G (2009) Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev. 32:425–33PubMedCrossRef
38.
Dirks MS, Butman JA, Kim HJ et al (2012) Long-term natural history of neurofibromatosis type 2-associated intracranial tumors. J Neurosurg. 117:109–17PubMedPubMedCentralCrossRef
39.
Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenheimer M (2004) Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 25:811–17PubMedCrossRef
40.
Plotkin SR, Merker VL, Muzikansky A, Barker FG 2nd, Slattery W 3rd (2014) Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol 35:e50–e56PubMedCrossRef
41.
Gugel I, Grimm F, Liebsch M et al (2019) Impact of surgery on long-term results of hearing in neurofibromatosis type-2 associated vestibular schwannomas. Cancers 11:1376PubMedPubMedCentralCrossRef
42.
Tosi U, Maayan O, An A et al (2022) Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis. J Neurooncol 156:431–441PubMedCrossRef
Metadaten
Titel
Natural history of hearing and tumor growth in vestibular schwannoma in neurofibromatosis type 2-related schwannomatosis
verfasst von
Takeshi Wakabayashi
Ryota Tamura
Kosuke Karatsu
Makoto Hosoya
Takanori Nishiyama
Yasuhiro Inoue
Kaoru Ogawa
Jin Kanzaki
Masahiro Toda
Hiroyuki Ozawa
Naoki Oishi
Publikationsdatum
05.04.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Oto-Rhino-Laryngology
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI
https://doi.org/10.1007/s00405-024-08601-4

Neu im Fachgebiet HNO

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise